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Novel Heparan Sulfate Mimetic Compounds
as Antitumor Agents
promoted by cell-surface HSGAGs acting as ligands for
P-selectin and/or as coreceptors for integrins [10]. On
the other hand, HSGAGs in the ECM act as a physical
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As regards structural characteristics, HSGAGs con-Saitama 357-8527
3 Graduate School of Science and Engineering sist of regions with high levels of sulfation and epimeriza-
tion (S domains), sequences with alternating N-acetylationSaitama University
255 Shimo-okubo, Sakura-ku, Saitama and N-sulfation (NA/S domains), and unmodified do-
mains that are mostly N-acetylated and contain littleSaitama 338-8570
Japan sulfate (unmodified domains) [16]. HSGAGs also consist
of a repeating structure of the disaccharide unit of hexu-
ronic acid (either iduronic acid or glucuronic acid) linked
to a glucosamine. There are 48 possible disaccharideSummary
units that result from the sulfation of the 2-O position
of uronic acid and the 6-O and 3-O positions of glucos-Heparan sulfate glycosaminoglycans (HSGAGs) are in-
amine and either the sulfation or acetylation of the Nvolved in tumor cell growth, adhesion, invasion, and
position of glucosamine. Even when HSGAGs consistmigration, due to their interactions with various pro-
of only six saccharides, there are 110,592 possible struc-teins. In this study, novel HSGAG-mimetic compounds
tures for these polysaccharides.(KI compounds) were designed and synthesized. As a
The enormous structural diversity of HSGAGs makesresult of cell-based assays, KI-105 was found to exert
it possible for them to interact with a wide variety ofpotent inhibitory activities against migration and inva-
proteins [17]. Such interactions make crucial contribu-sion of human fibrosarcoma HT1080 cells. The present
tions to the regulation of normal and pathological pro-results indicate that a novel invasion/migration inhibi-
cesses. In order to dissect a variety of the pathologicaltor, KI-105, can increase the adherence of HT1080
roles of HSGAGs and develop novel antitumor agents,cells. It was conceivable that this cellular effect was
we designed novel HSGAG-mimetic compounds (KIcaused by an increase in the amount of cell-surface
compounds) using database search techniques; more-HSGAGs and focal adhesions. Although further inves-
over, we took Lipinski’s “Rule of Five” [18] and moleculartigations are needed to decipher the molecular mecha-
dynamics calculations into consideration. Ease of or-nism of KI-105, it is suggested that heparanase and
ganic synthesis was also a major concern when design-Cdc42 are involved in its biological effects.
ing these mimetic compounds. Lipinski’s “Rule of Five”
is a simple mnemonic that states the characteristics
Introduction of compounds with poor absorbability or permeability
(there are more than 5 H-bond donors, 10 H-bond ac-
Heparan sulfate glycosaminoglycans (HSGAGs) have ceptors, the molecular weight is greater than 500, and
been found to play regulatory roles in many biological the calculated Lop P is greater than 5). Lop P is the
functions that include both normal physiological pro- partition coefficient of n-octanol/water [19].
cesses (e.g., embryogenesis) [1] and pathological
processes (e.g., tumorigenesis and metastasis) [2].
HSGAGs existing at the cell surface, as well as those in Results
the extracellular matrix (ECM), are complex and highly
sulfated polysaccharides that are ubiquitous in nearly Design and Synthesis of HSGAG-Mimetic Compounds
all animals. In vivo, HSGAGs usually exist as protein With the aim of developing antitumor agents, we fo-
conjugates referred to as heparan sulfate proteoglycans cused on a number of the pathological roles of HSGAGs.
(HSPGs) [3]. Syndecans [4] and glypicans [5] are the two First, we designed a novel mimetic structure for
main groups of cell-surface HSPGs. Perlecan [6] and agrin HSGAGs. Partial structures were searched based on the
[7] are the best-characterized HSPGs in the ECM. structure of the heparan sulfate (HS) disaccharide unit,
HSGAGs on cell surface regulate signal transduction HexUA-GlcNAc(6S) (where HexUA, GlcNAc, and 6S rep-
from the outside to the inside of tumor cells due to the resent hexuronic acid, N-acethyl-D-glucosamine, and
interaction of HSGAGs with various growth factors such 6-O-sulfate, respectively), from an in-house database
as bFGF [8] and VEGF [9]. Tumor-cell adhesion is also containing 50,000 compounds. Keeping ease of organic
synthesis in mind, 80 compounds obtained from the
database search were selected according to the Lip-*Correspondence: hisyo@riken.jp
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Figure 1. Discovery of Novel HSGAG-
Mimetic Compounds (KI Compounds)
(A) Protocol used for the discovery of a novel
HSGAG-mimetic structure. Chemical struc-
ture of a HS disaccharide unit (1), HexUA-
GlcNAc(6S), and 2-(3-nitrobenzoyl)benzoic
acid (2) are also shown.
(B) Energy-minimized structures of (1) and (2).
The arrows show the anionic functional
groups. The carbons of (1) and (2) are repre-
sented in green and pink, respectively. Oxy-
gen, nitrogen, and sulfur are represented in
red, blue, and yellow, respectively. The hy-
drogen atoms are not shown.
(C) Chemical structures of the KI compounds.
inski’s “Rule of Five.” The structures selected by this paclitaxel, was used as a positive control. The inhibition
method were energy minimized by molecular dynamics of the migration and invasion resulting from treatment
calculation. The results of calculations were compared with paclitaxel at 100 nM were 82% and 96%, respec-
with those for HexUA-GlcNAc(6S). Finally, we selected tively.
2-(3-nitrobenzoyl)benzoic acid as a core structure (Fig- The inhibitory activities exerted on the adhesion of
ure 1A). The energy-minimized structures of HexUA- HT1080 and HeLa cells to fibronectin were assessed
GlcNAc(6S) and 2-(3-nitrobenzoyl)benzoic acid revealed using Biocoat fibronectin coat plates. The RGD peptide
that anionic groups, such as sulfate, carboxylic acid, (GRGDNP, Gly-Arg-Gly-Asp-Asn-Pro), which inhibits cell
and nitro functional groups, are able to locate in similar adhesion to fibronectin [20], inhibited the adhesion of
positions and directions (Figure 1B). HSGAG-mimetic HeLa cells but not of HT1080 cells (Figure 2B). HS, pacli-
compounds were synthesized using 2-(4-fluorobenzoyl)- taxel, and the RGD control peptide (GRADSP, Gly-Arg-
benzoic acid (KI-101) as a starting material (Figure 1C). Ala-Asp-Ser-Pro; an inactive control for the RGD pep-
2-(4-Fluoro-3-nitrobenzoyl)benzoic acid (KI-102) was tide) did not inhibit the adhesion of either type of cells
obtained by the nitration of KI-101. KI-102 was treated to fibronectin. No KI compounds showed remarkable
with certain thiols, alcohols, and amines to give KI-103 inhibitory activities as regards the adhesion of either
through KI-110 (Figure 1C). type of cells to fibronectin (Figure 2B).
The inhibition of the growth of HT1080 cells induced
by KI compounds was then assessed using the WST-8The Antagonistic Effects of KI Compounds
assay (Figure 2C). Paclitaxel (100 nM) showed strongin Cell-Based Assays
inhibitory activity after incubation of the cells at 37CThe antagonistic effects of KI compounds against inva-
for 48 hr. However, it should be noted that at doses ofsion and migration of human fibrosarcoma HT1080 cells
up to 100M, none of KI compounds and HS possessedwere assessed using Biocoat Matrigel Invasion Cham-
growth inhibition activity.ber and Cell Culture Insert. KI-105 inhibited both inva-
As a result of these cell-based assays, we found thatsion and migration (Figure 2A). The inhibition percent-
KI-105 showed the most potent inhibition on tumor inva-ages of migration and invasion by KI-105 at 100 M
sion and migration among KI compounds. The concen-were 62% and 69%, respectively. Heparan sulfate (HS)
tration dependency of KI-105 as regards the inhibitioninhibited only invasion, and the inhibition at 100 M of
HS in disaccharide unit was 78%. A cytotoxic agent, of migration and invasion of HT1080 cells is shown in
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Figure 2. The Antagonistic Effects of KI Com-
pounds in Cell-Based Assays
(A) Inhibition of migration and invasion of
HT1080 cells by KI compounds. HT1080 cells
(2.5  104 cells) were incubated with KI com-
pounds (100 M), HS (100M in disaccharide
unit), or paclitaxel (100 nM) in chambers (mem-
brane pore size, 8 m) with or without Matri-
gel coating for 20 hr at 37C. After removing
the cells and the Matrigel from the upper side
of the membrane, the cells that had moved to
the lower side of the membrane were stained
with crystal violet and counted. The results
are the mean  SD of three experiments.
Black and hatched bars indicate migration
(without Matrigel) and invasion (with Matri-
gel), respectively.
(B) Inhibition of adhesion of HT1080 and HeLa
cells by KI compounds. HT1080 or HeLa cells
(6  104 cells) were incubated with KI com-
pounds (100 M), HS (100M in disaccharide
unit), RGD peptide (50M), RGD peptide con-
trol (50 M), or paclitaxel (1 M) for 1 hr at
37C on fibronectin precoated 96-well plates.
After washing the cells with PBS, adhering
cells were stained with crystal violet and
counted. The results are the mean  SD of
three experiments. Black and hatched bars
indicate HT1080 and HeLa cells, respectively.
(C) Inhibition of cell growth of HT1080 cells
by KI compounds. HT1080 cells (1 104 cells)
were incubated for 12 hr at 37C and were
then treated with KI compounds (100 M), HS
(100 M in disaccharide unit), or paclitaxel
(100 nM) for 48 hr at 37C. After incubation
with WST-8 for 2 hr at 37C, the absorbance
at 405 nm was measured. The results are the
mean  SD of three experiments.
Figure 3. KI-105 inhibited migration and invasion equally by washing, and that ectocellular HSGAGs remained at
the bottom. However, in the case of KI-105 treatment,(Figure 3A). The IC50 values of migration and invasion
the cells were not removed by washing (Figure 4Af).by KI-105 were 3.3 M and 2.5 M, respectively (Figure
These results indicate that KI-105 not only augmented3B). Tumor cell migration was also studied using an in
the amount of cell-surface HSGAGs but also augmentedvitro wound healing assay (Figure 3C). Confluent HT1080
the incidence of cell adhesion.cells were scratched (Figure 3Ca, time 0) and treated
The amount of cell-surface HSGAGs of HT1080 cellswith chemicals for 20 hr. After treatment with vehicle,
was also measured by flow cytometry (Figure 4B). CellHT1080 cells migrated and covered a great area of the
counts having high levels of log fluorescence intensityscratch (Figure 3Cb, control). On the other hand, KI-
increased in the KI-105 treatment (Figure 4B, red line)105 significantly inhibited the migration of HT1080 cells
as compared with nontreated cells (blue line). The maxi-(Figures 3Cc–3Ce).
mum value of the log fluorescence intensity was moved
from 80 to 500 by the KI-105 treatment.
Effects of KI-105 on the Phenotype of HT1080 Cells The incidence of cell adhesion was also assessed by
We measured the amount of cell-surface HSGAGs by the adhesion assay described Experimental Procedures
immunofluorescence staining (Figure 4A). After treat- (Figure 4C). The adherent HT1080 cell numbers were
ment of HT1080 cells with KI-105 for 24 hr, the amount significantly increased by KI-105 treatment for 24 hr
of cell-surface HSGAGs increased relative to that of against fibronectin, collagen IV, poly-Lys, and plastic
control (Figures 4Ab and 4Ae). The merge picture of the (Figure 4Ca). Pictures of the adherent cells against fibro-
control shows that HSGAGs were present not only at nectin in treatment with vehicle or KI-105 for 24 hr are
the cell surface but also in areas without cells (Figure shown in Figures 4Cb and 4Cc, respectively.
Focal adhesions were visualized by anti-vinculin anti-4Ac). This result indicates that the cells were peeled off
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Figure 3. Effects of KI-105 on Migration and Invasion of HT1080 Cells
(A) Inhibition of migration and invasion of HT1080 cells by KI-105. The experimental procedure was same as that described in Figure 2A.
HT1080 cells were incubated with vehicle or KI-105 at the indicated concentrations. Panels a–d show images of the migrated HT1080 cells
treated with vehicle (a), 1 M of KI-105 (b), 10 M of KI-105 (c), or 100 M of KI-105 (d) on the 8 m pore membrane. Panels e–h show images
of the invaded HT1080 cells treated with vehicle (e), 1 M of KI-105 (f), 10 M of KI-105 (g), or 100 M of KI-105 (h) on the 8 m pore
membrane.
(B) Bar graph of the results of (A). The results are the mean  SD of three experiments. Black and hatched bars indicate migration and
invasion, respectively.
(C) Migration analysis by in vitro wound healing assay. After incubation of HT1080 cells (5  105 cells/6-well plate) for 24 hr, an artificial wound
was created using P-10 pipette tip (a). The cells were treated with vehicle (b), 1 M of KI-105 (c), 10 M of KI-105 (d), or 100 M of KI-105
(e) for 20 hr.
body, as vinculin localizes at focal adhesions. The num- the amount of cell-surface HSGAGs, adherence, and
focal adhesions in HT1080 cells.ber of focal adhesions was significantly increased by
treatment with KI-105 for 24 hr (Figure 4De) in compari-
son with control (Figure 4Db). Focal adhesions were Effects of KI-105 on Several Proteins
We tested the inhibitory activities of KI-105 against sev-observed in the peripheral area of cells in the case of
vehicle treatment (Figure 4Dc). However, focal adhesions eral degradation enzymes, such as matrix metalloprotei-
nases (MMPs), coagulant factors, and heparanase, be-were located not only at the peripheral area but also the
inside area of cells in the case of KI-105 treatment (Fig- cause of their involvement in tumor invasion and
migration (Table 1) [21–23]. KI-105 was found to possessure 4Df). These results indicate that KI-105 augments
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Figure 4. Effects of KI-105 on the Phenotype
of HT1080 Cells
(A) Immunofluorescence staining of HT1080
cells. HT1080 cells were treated with vehicle
(a, b, c) or 100 M of KI-105 (d, e, f) for 24
hr. F-actin (red) and cell-surface HS (green)
were stained with Alexa Fluor 568 Phalloidin
and anti-HS antibody, respectively. White
bars indicate 10 m.
(B) FACS analysis of HT1080 cells. HT1080
cells were pretreated with vehicle for 48 hr.
The cells were incubated with (blue line) or
without (black line) anti-HS antibody and sub-
sequently incubated with secondary antibody.
HT1080 cells were pretreated with KI-105 (50
M) for 48 hr. The cells were incubated with
anti-HS antibody and incubated with second-
ary antibody (red line). The level of cell-sur-
face HSGAGs expression was analyzed by
flow cytometry.
(C) Adhesion assay of HT1080 cells. Panel a:
HT1080 cells were incubated with vehicle or
KI-105 (100 M) for 20 hr on fibronectin (FN),
collagen IV (CL), laminin (LM), poly-D-lysine
(LY), or plastic (PL) precoated 35 mm dishes.
After washing the cells with PBS, adherent
cells were stained with crystal violet and
counted. The results are the mean  SD of
three experiments. Hatched and black bars
indicate vehicle or KI-105 treated HT1080
cells, respectively. Panels b and c show im-
ages of the adherent HT1080 cells treated
with vehicle (b) or KI-105 (c) on fibronectin.
(D) Immunofluorescence staining of HT1080
cells. HT1080 cells were treated with vehicle
(a, b, c) or 100 M of KI-105 (d, e, f) for 20 hr.
F-actin (red) and vinculin (green) were stained
with Alexa Fluor 568 Phalloidin and anti-vin-
culin antibody, respectively. White bars indi-
cate 10 m.
heparanase inhibitory activity but did not inhibit the ac- M (Figure 5A). A correlation between the heparanase
inhibitory properties of KI-105 and the cellular effecttivity of MMP-2, MMP-9, collagenase, factor Xa, throm-
bin, trypsin, and urokinase-type plasminogen activator. was assessed using an anti-heparanase antibody (Fig-
ure 5B). The invasion and migration of HT1080 cells wereThe IC50 value of KI-105 against heparanase was 300
significantly inhibited by the anti-heparanase antibody
treatment as compared with the normal mouse IgG
Table 1. The Inhibitory Activities of KI-105 against Several treatment.
Degradation Enzymes The effect of KI-105 on several proteins implicated in
cell-matrix adhesion and cell migration was evaluatedInhibition
Enzyme Percentagea by Western blotting (Figure 5C). The amount of the Rho-
related small GTP binding protein Cdc42 was remark-MMPb-2 (human) 7.1  7.2
ably increased in the KI-105 treatment. The amount ofMMPb-9 (human) 21.2  7.4
paxillin was also increased slightly. However, amountsCollagenase 9.6  4.1
(Clostridium histolyticum) of other proteins assessed (Rac1, Rho, ILK, FAK, PAK,
Factor Xa (human) 0.1  1.3 NCK, phosphotyrosine, and -tubulin) were not altered
Thrombin (human) 26.1  9.2 by KI-105 treatment.
Trypsin (human pancreas) 4.3  0.6
uPAc (human urine) 5.1  6.2
Heparanase (human) 43.6  8.6
Molecular Basis of KI-105
a The concentration of KI-105 was 300 M. Novel heparan sulfate mimetic compound KI-105 was
b Matrix metalloproteinase. found to have weak inhibitory activity for heparanase
c Urokinase-type plasminogen activator.
and also found to increase the amount of the Rho-
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Figure 5. Effects of KI-105 on Several Pro-
teins
(A) Dose-response curve of heparanase inhi-
bition by KI-105. Cell lysate (2.0 mg/ml of pro-
tein) of HepG2-HP and HS (10 mg/ml in PBS,
pH 6.2) were incubated with vehicle or KI-105
for 24 hr at 37C. The reaction mixture was
subjected to SDS-PAGE (20%). After electro-
phoresis, the gel was stained with alcian blue.
The respective volumes of the bands were
measured using an MD Scanning Imager
equipped with MD ImageQuant Software Ver-
sion 3.22 (Molecular Dynamics, Inc.) for quan-
tification. The results are the mean  SD of
three experiments.
(B) Inhibition of migration and invasion of
HT1080 cells by anti-heparanase antibody.
The experimental procedure was the same
as that described in Figure 2A. HT1080 cells
were incubated with normal mouse IgG (67
g/ml) or anti-heparanase antibody (42 g/
ml) for 20 hr. The results are the mean  SD
of three experiments. Black and hatched bars
indicate migration and invasion, respectively.
(C) Western blotting analysis with specific an-
tibodies. HT1080 cells were incubated with
vehicle () or 100 M of KI-105 () for 20 hr.
related small GTP binding protein Cdc42. The mecha- Discussion
nism of how KI-105 increases the amount of Cdc42 has
been unclear until the present. So, we have assessed Most heparin or HS imitators are aimed at enhancing
the inhibition of tumor metastasis, arteriosclerosis, andthe molecular basis of KI-105 by interaction with he-
paranase and comparison with a very similar inactive inflammation; they are most often sulfated oligosaccha-
rides (e.g., heparin derivatives [25, 26], laminarin sulfatecompound, KI-110.
The results of database searches and site-directed [27], and chitin derivatives [28]). There are many difficul-
ties involved in the development of HSGAG-mimeticmutagenesis have suggested that mammalian heparan-
ase is related to members of glycosyl hydrolase families compounds, because HSGAGs carry out multiple func-
tions and are difficult to synthesize. Thus, low molecular10, 39, and 51, which have been predicted to have (/)8
TIM-barrel folds [24]. 1,4--xylanase from Penicillium weight HSGAG mimics with high specificity that are easy
to prepare are still needed. Some low molecular weightsimplicissimum is a member of the glycosyl hydrolase
family 10, and its X-ray structure has been determined. HSGAG mimics that are sulfated oligosaccharides have
been reported to show antitumor activities. Phospho-Therefore, homology modeling of heparanase was per-
formed using the X-ray structure of 1,4--xylanase from mannopentaose sulfate (PI-88) has been reported to
significantly inhibit tumor growth, metastasis, and an-Penicillium simplicissimum as a template. KI-105 was
manually located at the active site, under consideration giogenesis [29]. A pseudodisaccharide compound mim-
icking a unit of a HSGAG, designed as a heparanaseof the electrostatic interactions and hydrophobicity, and
then the structure of the heparanase/KI-105 complex inhibitor, was synthesized, and the inhibitory activity
against tumor cell heparanase was measured (IC50 valuewas energy minimized using molecular mechanics and
dynamic calculations (Figure 6A). The complex was sta- of 58–63 M) [30]. Such low molecular weight HSGAG
mimics are saccharide-based structures, although KIbilized by electrostatic interactions between Arg303 and
the carboxylic group of KI-105 and between Arg272 and compounds are not sugar-based compounds.
Novel HSGAG-mimetic compounds (KI compounds)the nitro group of the compound. 	-	 stacking between
Phe229 and the thiophenol group of KI-105 was also were designed and synthesized in the present study. As
a result of cell-based assays (i.e., migration, invasion,observed.
The energy-minimized structure of KI-110 was ob- adhesion, and growth assays), KI-105 was found to pos-
sess potent inhibitory activities on the invasion and mi-tained using the conformation of KI-105 in the heparan-
ase/KI-105 complex as a starting structure. The differ- gration of HT1080 cells. The IC50 values of migration and
invasion by KI-105 were 3.3 M and 2.5 M, respec-ence between KI-105 and KI-110 was the direction of
the benzene ring (Figures 6B and 6C). Torsion angles tively. The inhibitory activity of KI-105 on the migration
of HT1080 cells was also confirmed using in vitro woundA(1-2-3-4) and B(2-3-4-5) of KI-105 were 75.8 and 10.1,
respectively. Torsion angles A(1-2-3-4) and B(2-3-4-5) healing assay.
If the main mechanism of KI-105 is assumed to be arepresent the dihedral angles defined by the atoms 1,
2, 3, 4, and 5, which are indicated in Figure 6B. Torsion simple obstruction of the degradation of HSGAGs in the
ECM, only the invasion and not the migration of HT1080angles A(1-2-3-4) and B(2-3-4-5) of KI-110 were 108.6
and 73.7, respectively. The superimposed structures cells would be inhibited. Indeed, intact HS inhibited only
the invasion of HT1080 cells. However, KI-105 inhibitedof KI-105 and KI-110 are also shown in Figure 6C.
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1 hr did not change the adherence (Figure 2B). So KI-
105 was thought to change the character of HT1080
cells in 24 hr. KI-105 increased the number of focal
adhesion of HT1080 cells (Figure 4D). It is unclear how
the number of focal adhesion is augmented; however,
KI-105 remarkably increased the amount of Cdc42 (Fig-
ure 5C). Cdc42 is a member of the Rho family GTPases
and is well known to be involved in cell migration and
formation of focal complexes [31, 32]. So an increase
in the number of focal adhesion of HT1080 cells by KI-
105 may be under Cdc42’s control, but this assumption
needs further investigation.
KI-105 (100 M) moderately increased the amount of
cell-surface HSGAGs on HT1080 cells (Figures 4A and
4B). KI-105 also showed moderate inhibition of heparan-
ase (IC50 300 M, Figure 5A). Because only one heparan-
ase cDNA sequence coding functional enzyme has been
identified to date, heparanase has been considered a
major enzyme that degrades HSGAGs in mammalian
tissues [12–15] and human tumors [33]. Heparanase inhi-
bition by KI-105 may correlate with an increase in the
amount of cell-surface HSGAGs on HT1080 cells. There-
fore, it is conceivable that the increase in cell-surface
HSGAGs by KI-105 treatment was caused not by the en-
hancement of biosynthesis of HSGAGs but the inhibition
of degradation of cell-surface HSGAGs by heparanase.
Heparanase is well known to be involved in tumor
invasion and migration by two different mechanisms
[12–15]. One is the degradation of HSPGs in the ECM,
which is especially involved in invasion, because HSPGs
are known to be physical barriers against the invasion of
tumor cells. The other is the degradation of cell-surface
HSPGs (e.g., syndecans), which is a key mechanism of
cell spreading and migration. For example, syndecan-4 is
known to be located at sites of cell-matrix adhesion
[34], and it regulates cell spreading and migration in
cooperation with integrins [35, 36]. Thus, the present
findings indicating that heparanase inhibition by KI-105
results in inhibition of the invasion and migration of
HT1080 cells are consistent with previous reports. The
invasion and migration of HT1080 cells were also inhib-
Figure 6. Molecular Basis of KI-105 ited by the anti-heparanase antibody treatment (Figure
(A) Modeled structure of a heparanase/KI-105 complex model. KI- 5B). This result supports a correlation between the he-
105, active-site Glu residues, and the amino acid residues that inter- paranase inhibition and the invasion/migration inhi-
acted with KI-105 are indicated in boldface type. The atoms in KI-
bition.105 are represented in pink (carbon), white (hydrogen), red (oxygen),
Molecular modeling of the heparanase/KI-105 com-blue (nitrogen), and yellow (sulfur). The atoms in the amino acids,
plex and comparison between KI-105 (active) and a veryindicated in boldface type, are represented in sky blue (carbon), red
(oxygen), and blue (nitrogen). similar compound, KI-110 (inactive), revealed the molec-
(B) Energy-minimized structures of KI-105 and KI-110. The atoms ular basis of KI-105. 	-	 stacking between Phe-229 and
in KI-105 and KI-110 are represented in green (carbon), white (hydro- the thiophenol group of KI-105 was observed in the
gen), red (oxygen), blue (nitrogen), and yellow (sulfur). Yellow num-
heparanase/KI-105 complex model (Figure 6A). The di-bers are used for a definition of torsion angles.
rection of the benzene ring of thiophenol (KI-105) and(C) Superimposed structures of KI-105 and KI-110. Overlapped
phenol (KI-110) groups was different (Figures 6B andstructure is represented in white. Thiophenol of KI-105 and phenol
of KI-110 are represented in yellow and red, respectively. 6C). Based on these results, it may be possible to dis-
cover more potent antimigratory agents using KI-105 as
a lead compound.
both the invasion and the migration of HT1080 cells
(Figure 2A). These results suggest that KI-105 inhibited
the degradation of HSGAGs not only in the ECM but Significance
also on cell surface.
KI-105 treatment for 24 hr remarkably increased the During the past decade, HSGAGs have been recog-
nized to play important roles in the biology of cancer,adherence of HT1080 cells against fibronectin, collagen
IV, poly-lysine, and plastic (Figure 4C), but treatment for i.e., in tumorigenesis, tumor progression, and metas-
Chemistry & Biology
374
(Plymouth Meeting, PA). HS sodium salt from bovine kidney wastasis. Because of the unique structural features of
purchased from Seikagaku Corp (Tokyo, Japan).HSGAGs, which are highly sulfated oligosaccharides,
it has been difficult to develop nonsaccharide-based
Synthesis of CompoundsHSGAG regulators with low molecular weight. Many
2-(4-Fluoro-3-Nitrobenzoyl)Benzoic Acid (KI-102)known HSGAG regulators are derivatives of sulfated
A suspension of 11.0 g of 2-(4-fluorobenzoyl)benzoic acid (KI-101)
oligosaccharides. Here, we developed novel func- in 30 ml of fuming HNO3 was stirred at 4C for 2 hr and at room
tional regulators of HSGAGs that do not have a sac- temperature for 5 hr. The reaction mixture was poured into ice water
and extracted with chloroform. The chloroform extract was washedcharide-based structure. We selected 2-(3-nitroben-
with water, dried over anhydrous MgSO4, and concentrated in vacuo.zoyl)benzoic acid by database searches with regard
The residue was purified by a preparative medium pressure liquidto Lipinski’s “Rule of Five” and the ease of organic
chromatography (YAMAZEN Corp., Osaka, Japan) on silica gelsynthesis; molecular dynamics calculations were also
(chloroform:methanol 
 95:5). Yield, 22%; mp, 174–176C; 1H NMR
carried out as part of the selection process. A novel (500 MHz, acetone-d6) 7.49 (1H, d, J 7.5 Hz), 7.57 (1H, dd, J 8.5 Hz,
invasion/migration inhibitor, KI-105, was identified 10.5 Hz), 7.69 (1H, dd, J 7.5 Hz, 7.5 Hz), 7.77 (1H, dd, J 7.5 Hz, 7.5
Hz), 8.01 (1H, ddd, J 2.0 Hz, 4.0 Hz, 8.5 Hz) 8.08 (1H, d, J 7.5 Hz), 8.34among the 2-(3-nitrobenzoyl)benzoic acid derivatives
(1H, dd, J 2.0 Hz, 7.5 Hz); MS (FAB, Neg) m/z 288 (M-H); HRMS (FAB,(KI compounds), using cell-based assays (i.e., inva-
Neg) C14H7NO5F: calculated 288.0308, found m/z 288.0311 (M-H).sion, migration, adhesion, and growth assays). KI-105
2-(4-Ethylthio-3-Nitrobenzoyl)Benzoic Acid (KI-103)was found to increase the adherence of HT1080 cells.
A mixture of 76 mg of KI-102 and 28 mg of sodium ethanethioate
The amount of cell-surface HSGAGs and focal adhe- in 2 ml of 1,4-dioxane was stirred at room temperature for 4 hr and
sions were also increased by KI-105 treatment. To the was extracted with chloroform. The chloroform extract was purified
by a preparative medium pressure liquid chromatography (YAMA-best of our knowledge, this is the first report of a
ZEN Corp.) on silica gel (chloroform). Yield, 61%; 1H NMR (270 MHz,rationally designed and experimentally identified low
DMSO-d6) 1.30 (3H, t, J 5.5 Hz), 3.10 (2H, q, J 5.5 Hz), 7.37 (1H, d,molecular weight HSGAG-mimetic compound demon-
J 6.5 Hz), 7.61–7.81 (4H, m), 8.00 (1H, d, J 6.8 Hz), 8.27 (1H, br-s); MSstrating potent inhibition of the various functions in-
(FAB, Neg) m/z 330 (M-H); HRMS (FAB, Neg) C16H12NO5S: calculatedvolved in oncogenic processes. 330.0436, found m/z 330.0444 (M-H).
2-[4-(1, 2-Dicarboxyethyl)Thio-3-Nitrobenzoyl]Benzoic
Experimental Procedures Acid (KI-104)
A mixture of 100 mg of KI-102 and 52 mg of mercaptosuccinic acid
General Methods and 45 mg of DIPEA in 2 ml of 1,4-dioxane was stirred at room
The melting points of the synthesized compounds were measured temperature for 12 hr and was extracted with chloroform. The chloro-
with a Yanagimoto micro melting point apparatus (Yanagimoto, Ky- form extract was purified by a preparative medium pressure liquid
oto, Japan) and are presented here as uncorrected values. Proton chromatography (YAMAZEN Corp.) on silica gel (chloroform:metha-
NMR spectra were recorded on a JEOL JNM-EX270 spectrometer nol 
 95:5). Yield, 84%; 1H NMR (270 MHz, DMSO-d6) 2.81 (1H, dd,
(JEOL, Tokyo, Japan) or on a Varian UNITYplus 500 spectrometer J 5.7 Hz, 17.3 Hz), 2.93 (1H, dd, J 7.9 Hz, 17.3 Hz), 4.47 (1H, dd, J
(Varian, Palo Alto, CA). The chemical shifts were expressed in  5.7 Hz, 7.9 Hz), 7.49 (1H, d, J 7.0 Hz), 7.69 (1H, ddd, J 1.4 Hz, 7.6
units, using the solvent as an internal standard. The mass spectra Hz, 7.6 Hz), 7.76 (1H, ddd, J 1.4 Hz, 7.6 Hz, 7.6 Hz), 7.87 (1H, d, J
were obtained on a JEOL JMS-SX102 spectrometer (JEOL, Tokyo, 8.4 Hz), 7.99 (1H, d, J 8.4 Hz), 8.01 (1H, d, J 7.0 Hz), 8.25 (1H, d, J 1.6
Japan). All compounds for biological assays were dissolved in Hz); MS (FAB, Neg) m/z 418 (M-H); HRMS (FAB, Neg) C18H12NO9S:
DMSO. calculated 418.0233, found m/z 418.0249 (M-H).
2-[3-Nitro-4-(Phenylthio)Benzoyl]Benzoic Acid (KI-105)
Design and Computer Calculations A mixture of 226 mg of KI-102 and 86 mg of thiophenol and 101 mg
A HS disaccharide unit of HexUA-GlcNAc(6S) (where HexUA, of DIPEA in 3 ml of 1,4-dioxane was stirred at room temperature
GlcNAc, and 6S represent hexuronic acid, N-acethyl-D-glucos- for 12 hr and extracted with chloroform. The chloroform extract was
amine, and 6-O-sulfate, respectively) was used as a template struc- purified by a preparative medium pressure liquid chromatography
ture. Focusing on carboxylic acid and sulfate groups, a partial struc- (YAMAZEN Corp.) on silica gel (chloroform:methanol 
 95:5), and
ture search was carried out using the ISIS/Base (MDL Information then purified by reversed-phase HPLC using a PEGASIL ODS col-
Systems, San Leandro, CA) in combination with a two-dimensional umn (4.6  250 mm, Senshu Scientific Co. Ltd., Tokyo, Japan) with
structure database containing 50,000 compounds (i.e., both original 20%–100% CH3CN (0.05% TFA). Yield, 33%; mp, 138-140C; 1H
and commercial compounds). The eighty compounds obtained were NMR (270 MHz, DMSO-d6) 6.93 (1H, d, J 8.4 Hz), 7.45 (1H, d, J 7.3
automatically converted to three-dimensional structures using in- Hz), 7.60–7.80 (8H, m), 8.01 (1H, d, J 7.3 Hz), 8.33 (1H, s), 13.35 (1H,
house C programs, and then the structures were energy minimized br-s); MS (FAB, Neg) m/z 378 (M-H); HRMS (FAB, Neg) C20H12NO5S:
with Discover3 module of InsightII (Accelrys, San Diego, CA). The calculated 378.0436, found m/z 378.0450 (M-H).
energy minimization protocol was as follows: molecular mechanics, 2-[4-(4-Carboxyphenyl)Thio-3-Nitrobenzoyl]Benzoic
200 steps; molecular dynamics, 200 fs at 800 K; molecular dynamics, Acid (KI-106)
200 fs at 298 K; and molecular mechanics, 200 steps. The criteria A mixture of 217 mg of KI-102 and 117 mg of 4-mercaptobenzoic
for the selection of the HS mimics were the positions and directions acid and 97 mg of DIPEA in 5 ml of 1,4-dioxane was stirred at room
of anionic groups (i.e., sulfate, carboxylic acid, and nitro functional temperature for 12 hr and extracted with chloroform. The chloroform
groups) as well as the ease of organic synthesis and Lipinski’s “Rule extract was purified by a preparative medium pressure liquid chro-
of Five” [18]. matography (YAMAZEN Corp.) on silica gel (chloroform:methanol 

90:10). Yield, 37%; 1H NMR (270 MHz, DMSO-d6) 6.94 (1H, d, J 8.6
Hz), 7.23 (1H, m), 7.52 (2H, m), 7.65 (3H, m), 7.93 (1H, br-s), 8.03Chemicals
2-(4-fluorobenzoyl)benzoic acid, sodium ethanethioate, 1,4-dioxane, (2H, d, J 8.4 Hz), 8.25 (1H, s); MS (FAB, Neg) m/z 422 (M-H); HRMS
(FAB, Neg) C21H12NO7S: calculated 422.0334, found m/z 422.0334mercaptosuccinic acid, N,N-diisopropylethylamine (DIPEA), 4-mercap-
tobenzoic acid, ethylamine, cyclohexylamine, sodium ethoxide, and (M-H).
2-(4-Ethylamino-3-Nitrobenzoyl)Benzoic Acid (KI-107)sodium phenoxide trihydrate were purchased from Aldrich Chemical
Corp. (Milwaukee, WI). Fuming HNO3, thiophenol, and alcian blue A mixture of 85 mg of KI-102 and 1.2 ml of ethylamine (2.0 M solution
in tetrahydrofuran) and 76 mg of DIPEA in 2 ml of 1,4-dioxane was8GX were purchased from Wako Pure Chemical Industries (Osaka,
Japan). Paclitaxel was purchased from Sigma Chemical Co (St. stirred at room temperature for 2 hr and extracted with chloroform.
The chloroform extract was purified by a preparative medium pres-Louis, MO). RGD peptide (GRGDNP) and RGD control peptide
(GRADSP) were purchased from BIOMOL Research Laboratories sure liquid chromatography (YAMAZEN Corp.) on silica gel (chloro-
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form). Yield, 74%; 1H NMR (270 MHz, DMSO-d6) 1.29 (3H, t, J 6.8 35 mm dishes, collagen IV cellware 35 mm dishes, laminin cellware
35 mm dishes, or poly-D-lysine cellware 35 mm dishes (BectonHz), 3.52 (2H, dq, J 5.7 Hz, 6.8 Hz), 7.20 (1H, d, J 9.2 Hz), 7.39 (1H,
d, J 6.8 Hz), 7.64–7.74 (2H, m), 7.85 (1H, d, J 9.2 Hz), 8.05 (1H, d, J Dickinson Labware, Bedford, MA). After the addition of vehicle,
compounds, HS, RGD peptide, RGD control peptide, or paclitaxel,7.8 Hz), 8.25 (1H, d, J 1.9 Hz), 8.64 (1H, t, J 5.7 Hz); MS (FAB, Neg)
m/z 313 (M-H); HRMS (FAB, Neg) C16H13N2O5: calculated 313.0824, the plate was incubated at 37C for 1 hr. After washing the plate
with PBS, adhered cells were fixed with glutaraldehyde and stainedfound m/z 313.0835 (M-H).
2-(4-Cyclohexylamino-3-Nitrobenzoyl)Benzoic Acid (KI-108) with crystal violet. Cells from various regions of the wells were
then counted, and the inhibition percentage was calculated by theA mixture of 98 mg of KI-102 and 67 mg of cyclohexylamine and
88 mg of DIPEA in 2 ml of 1,4-dioxane was stirred at room tempera- following equation: [inhibition % 
 100  (cell number of the
chemical-treated experiment)/(cell number of the vehicle-treatedture for 2 hr and extracted with chloroform. The chloroform extract
was purified by a preparative medium pressure liquid chromatogra- experiment)  100].
phy (YAMAZEN Corp.) on silica gel (chloroform). Yield, 43%; 1H NMR
(270 MHz, DMSO-d6)  1.06–1.95 (10H, m), 3.48 (1H, m), 7.19 (2H, m), Cell Viability Assay
7.53 (2H, m), 7.76 (1H, d, J 8.9 Hz), 7.98 (1H, d, J 7.3 Hz), 8.14 (1H, s),
The viability of tumor cells was measured by the WST-8 {2-(2-
8.29 (1H, d, J 9.5 Hz); MS (FAB, Neg) m/z 367 (M-H); HRMS (FAB,
methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-
Neg) C20H19N2O5: calculated 367.1294, found m/z 367.1336 (M-H). tetrazolium} assay [39]. 0.1 ml of cell suspension (1  105 cells/ml)
2-(4-Ethoxy-3-Nitrobenzoyl)Benzoic Acid (KI-109)
was incubated at 37C for 12 hr. Cells were treated with vehicle,A mixture of 71 mg of KI-102 and 0.1 ml of sodium ethoxide (21 wt.
compounds, HS, or paclitaxel at 37C for 48 hr. Ten microliters of% solution in denatured ethyl alcohol) in 2 ml of 1,4-dioxane was
WST-8 monosodium salt solution (5 mM) (Nacalai Tesque, Kyoto,stirred at room temperature for 3 hr and extracted with chloroform
Japan) was added to the wells, and the mixtures were incubated atunder acidic conditions. The chloroform extract was purified by
37C for 2 hr. The absorbance was measured at 450 nm. The growtha preparative medium pressure liquid chromatography (YAMAZEN
inhibition percentage was calculated by the following equation:Corp.) on silica gel (chloroform:methanol 
 90:10). Yield, 55%; 1H
[growth inhibition % 
 100  (A  B )/(C  B )  100], where A isNMR (270 MHz, DMSO-d6) 1.34 (3H, t, J 6.8 Hz), 4.26 (2H, q, J 6.8
the absorbance of a chemical-treated experiment, B is the ab-Hz), 7.25 (1H, m), 7.39 (1H, d, J 8.9 Hz), 7.56 (2H, m), 7.72 (1H, d, J
sorbance of cell-free experiment, and C is the absorbance of the9.2 Hz), 7.98 (2H, m); MS (FAB, Neg) m/z 314 (M-H); HRMS (FAB,
vehicle-treated experiment.Neg) C16H12NO6: calculated 314.0665, found m/z 314.0679 (M-H).
2-(4-Phenoxy-3-Nitrobenzoyl)Benzoic Acid (KI-110)
A mixture of 78 mg of KI-102 and 46 mg of sodium phenoxide Wound Healing Assay
trihydrate in 2 ml of 1,4-dioxane was stirred at room temperature HT1080 cells (5  105 cells/6-well plate) were incubated in dishes
for 5 hr and extracted with chloroform under acidic conditions. The for 24 hr. An artificial wound was carefully created using a plastic
chloroform extract was purified by a preparative medium pressure tip to scratch the subconfluent cell monolayer. The medium was
liquid chromatography (YAMAZEN Corp.) on silica gel (chloroform). changed, the cells were treated with chemicals for 20 hr, and photo-
Yield, 99%; 1H NMR (270 MHz, DMSO-d6) 7.07 (1H, d, J 8.6 Hz), 7.18 graphs were taken.
(2H, dd, J 1.4 Hz, 7.8 Hz), 7.27–7.36 (2H, m), 7.46–7.52 (2H, m),
7.57–7.67 (2H, m), 7.79 (1H, br-d, J 8.4 Hz), 8.01 (1H, br-d, J 6.8 Hz),
Immunofluorescence Staining8.18 (1H, br-s), 8.33 (1H, br-s); MS (FAB, Neg) m/z 362 (M-H); HRMS
HT1080 cells were seeded on glass coverslips at a concentration(FAB, Neg) C20H12NO6: calculated 362.0665, found m/z 362.0655
of 2.5  104 cells/well of a 6-well plate for 12 hr in DMEM containing(M-H).
10% FCS; the cells were then incubated for 24 hr with either vehicle
or KI-105. Then, the cells were washed with PBS and fixed with 4%Cell Culture
paraformaldehyde at room temperature for 20 min. The cells wereHuman fibrosarcoma HT1080 cells and HeLa cells were grown in
washed with PBS and incubated with monoclonal antibody againstDulbecco’s modified Eagle’s medium (DMEM) supplemented with
HS (10E4 epitope, Seikagaku Corp., Tokyo, Japan) at room tempera-10% FCS. HepG2-HP cells, which are stable transfectants of human
ture for 1 hr, followed by incubation with Alexa Fluor 488-labeledhepatocellular carcinoma HepG2 cells expressing a high level of
goat anti-mouse IgM (Molecular Probes Inc., Eugene, OR) for 1 hr.recombinant human heparanase [37], were grown in DMEM supple-
The cells were washed with PBS and incubated with Alexa Fluormented with 10% FCS and 50 g/ml of G418 (Geneticin, Gibco Life
568 phalloidin (Molecular Probes Inc., Eugene, OR) for 1 hr underTechnologies, Grand Island, NY). All cell lines were incubated at
dark conditions to visualize the actin cytoskeleton. Monoclonal anti-37C in a humidified atmosphere of 5% CO2/95% air.
body against human vinculin (SIGMA, St. Louis, MO) was used to
visualize focal adhesions. The coverslips were mounted on glassInvasion and Migration Assay
slides and visualized using a fluorescence microscope (Olympus,In vitro invasion and migration activities were assessed using the
Tokyo, Japan).method of Albini et al. [38]. BD BioCoat Matrigel Invasion Chamber
and Cell Culture Insert (8 M pore size, Becton Dickinson Labware,
Bedford, MA) were used for invasion and migration assays, respec- Fluorescence-Activated Cell Sorting (FACS)
tively. The chambers were placed on 24-well plates. Then, 0.5 ml HT1080 cells were incubated with vehicle or KI-105 for 48 hr. The
of tumor cell suspension (5  104 cells/ml) in DMEM (0% FCS) was cells were collected by centrifugation (1000 rpm, 3 min) and washed
added to the upper layer, and 0.75 ml of DMEM (10% FCS) was with PBS. Then, the cells were incubated with monoclonal antibody
added to the lower layer. After adhesion for 1 hr, vehicle, com- against HS (10E4 epitope, Seikagaku Corp., Tokyo, Japan) at 4C
pounds, HS, paclitaxel, normal mouse IgG (Santa Cruz Biotechnol- for 30 min, followed by incubation with Alexa Fluor 488-labeled goat
ogy, Santa Cruz, CA), or anti-heparanase antibody (BD Biosciences, anti-mouse IgM (Molecular Probes Inc., Eugene, OR) at 4C for 30
San Jose, CA) was added to the upper and lower layers. After incu- min. Cell-surface HS expression was analyzed by BD FACSCalibur
bation for 20 hr at 37C, the tumor cells and Matrigel on the upper flow cytometry (BD Biosciences, San Jose, CA).
surface of the membrane were completely removed by wiping with
cotton swabs. Cells on the lower surface of the membrane were
Matrix Metalloproteinases (MMPs) Inhibition Assayfixed in methanol and stained with crystal violet. Cells from various
The inhibitory activities against MMP-2 (gelatinase A, 72 kDa typeregions of the membrane were counted, and the inhibition percent-
IV collagenase) or MMP-9 (gelatinase B, 92 kDa type IV collagenase)age was calculated by the following equation: [inhibition %
 100
were assessed using the MMP-2 or MMP-9 Colorimetric Assay Kit(cell number of the compound-treated experiment)/(cell number of
for Drug Discovery (BIOMOL Research Laboratories, Inc., Plymouththe vehicle-treated experiment)  100].
Meeting, PA). The Enz Chek Gelatinase/Collagenase Assay Kit (Mo-
lecular Probe, Inc., Eugene, OR) and a MICROTEST 96-Well AssayAdhesion Assay
Plate, Optilux (Becton Dickinson Labware, Bedford, MA) were usedThe tumor cell suspension in DMEM (0% FCS) was added to 96-
well BIOCOAT fibronectin coat plate, human fibronectin cellware for the Clostridium collagenase inhibition assay.
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Coagulant Factors Inhibition Assay 240, 367–370/248–251, 375–388/263–276, 394–411/285–302. Struc-
ture construction and molecular dynamics calculations were carriedA reaction mixture of enzyme, KI-105, and chromogenic substrate
in PBS (pH 7.0) was incubated at room temperature for 15 min. The out by the Biopolymer and Discover3 modules of Discover/InsightII
program (Accelrys Inc., San Diego, CA) using the X-ray structure ofabsorbance at 405 nm was measured. The chromogenic substrate
S-2222 (Chromogenix Instrumentation Laboratory S.p.A., Milano, 1,4--xylanase (Protein Data Base entry 1BG4) as a template.
Italy) was used for the assays of human factor Xa (Enzyme Research
Laboratories, South Bend, IN) and human trypsin (Athens Research Supplemental Data
and Technology, Athens, GA). The chromogenic substrate S-2238 Supplemental data including the effect of KI-105 and HPLC-purified
(Chromogenix Instrumentation Laboratory S.p.A., Milano, Italy) was KI-105 on the migration and invasion of HT1080 cells, purification
used for the assay of human  thrombin (Enzyme Research Labora- data of heparanase and inhibitory activity of KI-105 against semipur-
tories, South Bend, IN) [40]. Phenylmethanesulfonyl fluoride (PMSF) ified heparanase, and amino acid sequence alignment of heparan-
was used as the positive control for thrombin, and a trypsin inhibitor ase and 1,4--xylanase are available at http://www.chembiol.com/
from Glycine max (soybean, SIGMA, St. Louis, MO) was used as the cgi/content/full/11/3/367/DC1.
positive control for factor Xa and trypsin.
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